Corindus Announces 100th Robotic-Assisted PCI Procedure Performed Using 2nd Generation CorPath® GRX System

Get Instant Instagram Followers and Likes with GetInsta

GetInsta App is 100% safe and secure to get benefits from online smart feature plans. There are lots of reliable and smart feature explorations to achieve your objectives. Learn more!

Philips Introduces Integrated Interventional Hemodynamic System with Patient Monitor IntelliVue X3

The integration provides the opportunity for monitoring during image-guided procedures on the Philips Image Guided Therapy System – Azurion, improving workflow with comprehensive patient records that support timely clinical decision-making during interventional cardiology procedures and beyond.

Lawson Health Research Institute Found Simple Device Improves Care After Kidney Transplantation

The geko™ device, manufactured by Sky Medical Technology Ltd and distributed in Canada by Trudell Healthcare Solutions Inc., is a muscle pump activator that significantly improves blood flow by stimulating the body’s ‘muscle pumps.’

Corindus Vascular Robotics, Inc. (NYSE MKT: CVRS) announced today the milestone of the 100th robotic-assisted percutaneous coronary intervention (PCI) case performed using the Company’s second-generation CorPath GRX System. Since its commercial launch in January 2017, the CorPath GRX System has been used successfully in a variety of procedural settings and physicians have reported an increase in the number of procedures that can be performed robotically.

Sunil Rao, MD, Section Chief of Cardiology at the Durham VA Medical Center, stated, “The CorPath GRX System is an important advancement in the field of interventional cardiology and I am pleased to be a part of the initial launch of this enhanced technology. The addition of active guide management has allowed me to increase the number of interventional procedures I perform robotically, and as a result, I was able to complete several difficult cases entirely using the CorPath GRX System.”

The CorPath GRX System offers improvements in procedural control, enhanced workflow and radiation protection for physicians, patients and staff. Since its commercial launch, the CorPath GRX System has been used successfully in a variety of PCI cases including complex multi-vessel disease, NSTEMI, left radial access, diffused and calcified lesions, FFR, ostial RCA and subtotal 99% occlusions.

“The completion of the first 100 cases using our CorPath GRX System represents a significant milestone for Corindus,” said Mark Toland, President and CEO of Corindus. “The early feedback from our customers has been positive and we are excited to continue our U.S. commercial roll-out throughout the rest of this year.”

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine here.

Related Articles